A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

New England Journal of Medicine

Volumn 344, Issue 22, 2001, Pages 1659-1667

  Eichhorn, ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BUCINDOLOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SPIRONOLACTONE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; AGED; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 0035978801     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200105313442202     Document Type: Article

References (42)

1. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
2. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
3. Conn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
4. Kay DM, Lefkovits I, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-63.
5. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87:Suppl V:V-140-V-148.
6. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987;75:Suppl IV:IV-80-IV-92.
7. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayhurn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
8. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of β-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79:794-8.
9. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J 1993;126:1042-7.
10. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-16. [Erratum, N Engl J Med 1999;341:298.]
11. The BEST Steering Committee. Design of the Beta Blocker Evaluation of Survival Trial (BEST). Am J Cardiol 1995,75:1220-3.
12. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
13. Efron B. Forcing a sequential experiment to be balanced. Biometrika 1971;58:403-17.
14. Lakatos E. Sample size determination in clinical trials with time dependent rates of losses and noncompliance. Control Clin Trials 1986;7: 189-99.
15. Idem. Sample size based on the log-rank statistic in complex clinical trials. Biometrics 1988;44:229-41. [Erratum, Biometrics 1988;44:923.]
16. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
17. Lan KKG, Rosenberger WF, Lachin JM. Use of spending functions for occasional or continuous monitoring of data in clinical trials. Stat Med 1993;12:2219-31.
18. Lan KKG, Lachin JM. Implementation of group sequential logrank tests in a maximum duration trial. Biometrics 1990;46:759-70.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. SAS (r) proprietary software, release 6.12. Cary, N.C.: SAS Institute, 1996.
21. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34: 187-202.
22. S-PLUS: version 3.4. Seattle: Insightful, 1998 (software).
23. Harrell FE. Predicting outcomes: applied survival analysis and logistic regression. Charlottesville: School of Medicine, University of Virginia, 1996.
24. Idem. Design and Hmisc S-PLUS function libraries: S-PLUS 2000. Seattle: Insightful, June 1999 (software).
25. Materson BJ, Reda DJ, Cushman WC, et al. Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-21. [Erratum, N Engl J Med 1994; 330:1689.]
26. Johnson JA, Burlew BS, Stiles RN. Racial differences in beta-adrenoceptor-mediated responsiveness. J Cardiovasc Pharmacol 1995;25:90-6.
27. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure trials. J Card Fail 1999;5:178-87.
28. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344: 1351-7.
29. Yancy C, Fowler MB, Colucci WS, Gilbert EM, Lukas MA, Young ST. Response of black heart failure patients to carvedilol. J Am Coll Cardiol 1997;29:Suppl A:284A. abstract.
30. Freudenberger R, Kalman J, Mannino M, Buchholz-Varley C, Ocampo O, Kukin M. Effect of race in the response to metoprolol in patients with congestive heart failure secondary to idiopathic dilated or ischecmic cardiomyopathy. J Am Coll Cardiol 1997;80:1372-4.
31. Bloem LJ, Manatunga AK, Pratt JH. Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension 1996;27:62-6.
32. Rotimi C, Puras A, Cooper R. Polymorphisms of renin-angiotensin genes among Nigerians, Jamaicans, and African Americans. Hypertension 1996;27:558-63.
33. Moore JD, Mason DA, Green SA, Hsu J, Liggett SB. Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat 1999;14:271.
34. Hershherger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 1990;15:959-67.
35. Sederberg J, Wichman SE, Lindenfeld J, et al. Bucindolol has no intrinsic sympathomimetic activity (ISA) in nonfailing human ventricular preparations. J Am Coll Cardiol 2000;35:Suppl A:207A. abstract.
36. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9.
37. Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third generations β-blocking agents in chronic heart failure. Clin Cardiol 1998;21:Suppl 1:1-3-1-13. [Erratum, Clin Cardiol 1999;22:ia.]
38. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17:Suppl B:8-16.
39. 1,-adrenoceptors in the cardiac sympathetic nerves of the dog: effects of prazosin and yohimbine on sympathetic neurotransmission to the heart. Eur J Pharmacol 1984;103:51-6.
40. Lowes BD, Lindenfeld JA, Gilbert EM, et al. Differential effects of β-blocking agents on adrenergic activity. Circulation 2000;102:Suppl II: II-628-II-629. abstract.
41. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94: 2817-25.
42. Coats AJS. Heart Failure 99 - in MOXCON story. Int J Cardiol 1999;71:109-11.